An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01386580

Recruitment Status : Completed

First Posted : July 1, 2011

Last Update Posted : January 22, 2015

Sponsor:

Information provided by (Responsible Party):

BBB-Therapeutics B.V.

Study Description

Brief Summary:

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of 2B3-101 both as single agent and in combination with trastuzumab. Furthermore, the study will explore the preliminary antitumor activity of 2B3-101 as single agent in patients with with solid tumors and brain metastases or recurrent malignant glioma as well as in patients with various forms of breast cancer with and in combination with trastuzumab in HER2+ breast cancer patients with brain metastases.

Condition or disease	Intervention/treatment	Phase
Brain Metastases Lung Cancer Breast Cancer Melanoma Malignant Glioma	Drug: 2B3-101 Drug: Trastuzumab Drug: 2B3-101 60 mg/m2 every 4 weeks Drug: 2B3-101 50 mg/m2 every 3 weeks	Phase 1 Phase 2

Show Detailed Description

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	84 participants
Allocation:	Non-Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Study Start Date :	July 2011
Actual Primary Completion Date :	December 2014
Actual Study Completion Date :	December 2014

Resource links provided by the National Library of Medicine

Genetic and Rare Diseases Information Center resources: Glioma Neuroepithelioma

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: 2B3-101 Single Agent Dose Escalation Patients in single agent dose escalation arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.	Drug: 2B3-101 IV every 21 days Other Name: Glutathione pegylated liposomal doxorubicin hydrochloride
Experimental: 2B3-101 in combination with trastuzumab HER2+ breast cancer patients with brain metastases will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. As long as 2B3-101 is well tolerated, the remaining 95% of the infusion could thereafter be administered over the next 60 min, resulting in a total infusion time of 90 minutes. The infusion of trastuzumab will then follow 30 minutes after the completion of the 2B3-101 infusion.	Drug: 2B3-101 IV every 21 days Other Name: Glutathione pegylated liposomal doxorubicin hydrochloride Drug: Trastuzumab IV every 21 days Other Name: Herceptin
Experimental: 2B3-101 solid tumor expansion Patients in the breast, Small Cell Lung Cancer and melanoma dose expansion arms will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.	Drug: 2B3-101 50 mg/m2 every 3 weeks IV every 21 days Other Name: Glutathione pegylated liposomal doxorubicin hydrochloride
Experimental: 2B3-101 glioma expansion Patients in the single agent glioma dose expansion arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.	Drug: 2B3-101 60 mg/m2 every 4 weeks IV every 28 days Other Name: Glutathione pegylated liposomal doxorubicin hydrochloride

Outcome Measures

Primary Outcome Measures :

To characterize the safety and tolerability of intravenously administered 2B3-101 in patients with advanced solid tumors and metastatic brain cancer or recurrent malignant glioma. [ Time Frame: 16 months ]
To identify the maximum tolerated dose (MTD) of of intravenously administered 2B3-101 in patients with advanced solid tumors and metastatic brain cancer or recurrent malignant glioma. [ Time Frame: 16 months ]
To assess the safety and tolerability of intravenously (IV) administered 2B3-101 in combination with trastuzumab, in patients with HER2+ breast cancer with brain metastases [ Time Frame: 9 months ]
To identify the maximum tolerated dose (MTD) of of intravenously administered 2B3-101 in combination with trastuzumab in patients with HER2+ breast cancer with brain metastases [ Time Frame: 9 months ]

Secondary Outcome Measures :

Examine the pharmacokinetics (PK) in plasma of intravenously administered 2B3-101 in terms of Cmax, Vss, T1/2, AUC, CL; [ Time Frame: 16 months ]
Obtain preliminary information on the clinical anti-tumor activity of intravenously administered 2B3-101 on brain metastases secondary to breast cancer in terms of objective response rate. [ Time Frame: 16 months ]
Obtain preliminary information on the clinical anti-tumor activity of intravenously administered 2B3-101 on brain metastases secondary to breast cancer in terms of duration of response. [ Time Frame: 16 months ]
Obtain preliminary information on the clinical anti-tumor activity of intravenously administered 2B3-101 on recurrent malignant glioma in terms of objective response rate. [ Time Frame: 16 months ]
Obtain preliminary information on the clinical anti-tumor activity of intravenously administered 2B3-101 on recurrent malignant glioma in terms of duration of response. [ Time Frame: 16 months ]
Examine the pharmacokinetics (PK) in plasma of intravenously administered 2B3-101 in combination with trastuzumab in terms of Cmax, Vss, T1/2, AUC, CL; [ Time Frame: 9 months ]
Obtain preliminary information on the clinical anti-tumor activity of intravenously administered 2B3-101 in combination with trastuzumab on brain metastases secondary to HER2+ breast cancer in terms of objective response rate. [ Time Frame: 9 months ]
Obtain preliminary information on the clinical anti-tumor activity of intravenously administered 2B3-101 in combination with trastuzumab on brain metastases secondary to HER2+ breast cancer in terms of duration of response. [ Time Frame: 9 months ]
Obtain preliminary information on the clinical anti-tumor activity of intravenously administered 2B3-101 on brain metastases secondary to SCLC cancer in terms of objective response rate. [ Time Frame: 6 months ]
Obtain preliminary information on the clinical anti-tumor activity of intravenously administered 2B3-101 on brain metastases secondary to melanoma in terms of objective response rate. [ Time Frame: 6 months ]
Obtain preliminary information on the clinical anti-tumor activity of intravenously administered 2B3-101 on brain metastases secondary to SCLC cancer in terms of duration of response. [ Time Frame: 6 months ]
Obtain preliminary information on the clinical anti-tumor activity of intravenously administered 2B3-101 on brain metastases secondary to melanoma in terms of duration of response. [ Time Frame: 6 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age ≥ 18 years.
Measurable intracranial disease by MRI.
ECOG Performance Status ≤ 2.
Estimated life expectancy of at least 8 weeks.
Toxicities incurred as a result of previous anticancer therapy (radiation therapy, chemotherapy, or surgery) must be resolved to ≤ grade 2 (as defined by CTCAE version 4.0).
No evidence of (cortical) cognitive impairment as defined by a Mini-Mental Status Exam (MMSE) score ≥ 25/30.
Written informed consent according to local guidelines.

In addition to the above listed eligibility criteria, the following criteria are applicable:

2B3-101 single agent dose-escalation phase:
1. Patients with pathologically confirmed diagnosis of advanced, recurrent solid tumors and unequivocal evidence of brain metastases that are refractory to standard therapy or for whom no standard therapy exists or with unequivocal evidence of newly diagnosed untreated brain metastases and controlled extracranial disease which per the multi-disciplinary team decision do not require immediate radiotherapy, surgery or standard systematic chemotherapy. Brain metastases may be stable, progressive, symptomatic or asymptomatic brain metastasis/es. Stable or decreasing dosage of steroids (e.g. dexamethasone) for 7 days prior to baseline MRI or non-enzyme inducing anti-epileptic drugs is allowed.
  
  Or -
2. Patients with pathology confirmed diagnosis of advanced, recurrent primary malignant (grade III and IV) glioma that are refractory to standard therapy or for whom no standard therapy exists. Stable or decreasing dosage of steroids (e.g. dexamethasone) for 7 days prior to baseline MRI or non-enzyme inducing anti-epileptic drugs are allowed.
2B3-101 in combination with trastuzumab dose escalation phase:

Patients with histologically-confirmed HER2-positive (IHC 3+ or fluorescence in situ hybridization [FISH] amplified; by clinical assay on either primary or metastatic tumor) adenocarcinoma of the breast with unequivocal evidence of brain metastases that are refractory to standard therapy or for which no standard therapy exist or with unequivocal evidence of newly diagnosed untreated brain metastases and controlled extracranial disease which per the multi-disciplinary team decision do not require immediate radiotherapy, surgery or standard systematic chemotherapy can be included to this escalation phase as well.

- Breast cancer brain metastases expansion phase:

Patients with pathologically confirmed diagnosis of advanced, recurrent breast cancer with at least one progressive and/or new metastatic brain lesion, that are refractory to standard therapy or for whom no standard therapy exist. Brain metastases may be stable, progressive, symptomatic or asymptomatic brain metastasis/es. Stable or decreasing dosage of steroids (e.g. dexamethasone) for 7 days prior to baseline MRI or non-enzyme inducing anti-epileptic drugs is allowed.

Or -
Patients with pathologically confirmed diagnosis of advanced breast cancer with newly diagnosed, untreated, brain metastases and controlled extracranial disease which per the multi-disciplinary team decision do not require immediate radiotherapy, surgery or standard systematic chemotherapy.

SCLC brain metastases study arm of the expansion phase:

Patients with pathologically confirmed diagnosis of advanced, recurrent SCLC with at least one progressive and/or new metastatic brain lesion that are refractory to standard therapy or for whom no standard therapy exist. Stable or decreasing dosages of steroids (e.g. dexamethasone) for 7 days prior to baseline MRI and/or use of non-enzyme inducing anti-epileptic drugs are allowed.

Or
Patients with pathologically confirmed diagnosis of advanced SCLC with newly diagnosed, untreated, brain metastases and controlled extracranial disease which per the multi-disciplinary team decision do not require immediate radiotherapy, surgery or standard systematic chemotherapy.

Melanoma brain metastases study arm of the expansion phase:

Patients with pathologically confirmed diagnosis of advanced, recurrent melanoma with at least one progressive and/or new metastatic brain lesion that are refractory to standard therapy or for whom no standard therapy exist. Stable or decreasing dosages of steroids (e.g. dexamethasone) for 7 days prior to baseline MRI and/or use of non-enzyme inducing anti-epileptic drugs are allowed.

Or
Patients with pathologically confirmed diagnosis of advanced melanoma with newly diagnosed, untreated, brain metastases and controlled extracranial disease which per the multi-disciplinary team decision do not require immediate radiotherapy, surgery or standard systematic chemotherapy.

Recurrent malignant glioma study arm of the expansion phase:

7 patients with histologically proven glioma grade IV, which is progressive following first line treatment with surgery or biopsy followed by fractionated radiotherapy with concurrent temozolomide-containing chemotherapy.

and
7 patients with recurrent histologically confirmed malignant (WHO grade III and IV) glioma or histologically confirmed low-grade (WHO grade II) glioma with radiographic evidence of malignant transformation by MRI, that are refractory to standard therapy, or for whom no standard therapy exists or do not require immediate standard therapy per the multi-disciplinary team decision. Patients in both groups should have stable or decreasing dosage of steroids (e.g. dexamethasone) for a minimum of 7 days prior to baseline MRI. Non-enzyme inducing anti-epileptic drugs are allowed

Exclusion Criteria.
- Prior Treatment. 1. Less than 1 week since the last treatment of lapatinib, less than 2 weeks since the last treatment of vemurafenib, less than 4 weeks since the last treatment of chemotherapy, biological therapy, immunotherapy and systemic radiotherapy (except palliative radiation delivered to <20% of bone marrow), less than 8 weeks for cranial radiotherapy, and less than 6 weeks for nitrosoureas and mitomycin C.
  
  2. Patients that have received a maximum cumulative dose of free (i.e., non-liposomal) or liposomal doxorubicin > 360mg/m2 or free epirubicin > 600mg/m2.
- Current Treatment. 3. Current or recent (within 30 days of first study treatment) treatment with another investigational drug or participation in another investigational study.
- Hematology, coagulation and biochemistry. 4. Inadequate bone marrow function: Absolute Neutrophil Count (ANC): < 1.5 x 109/L, or platelet count < 100 x 109/L or hemoglobin < 6 mmol/L.
  
  5. Inadequate liver function, defined as:
  
  • Serum (total) bilirubin > 1.5 x the ULN for the institution if no liver metastases (> 2 x ULN in patients with liver metastases);
  
  • ASAT or ALAT > 2.5 x ULN if no liver metastases (> 4 x ULN in patients with liver metastases);
  - Alkaline phosphatase levels > 2.5 x ULN if no liver metastases (> 5 x ULN in patients with liver metastases, or > 10 x ULN in patients with bone metastases).
    
    6. Inadequate renal function, defined as:
  - Serum creatinine > 1.5 x ULN.
- Other. 7. Leptomeningeal carcinomatosis as the only site of CNS involvement. 8. Pregnancy or lactation. Serum pregnancy test to be performed within 7 days prior to study treatment start, or within 14 days followed by a confirmatory urine pregnancy test within 7 days prior to study treatment start.
  
  9. For female subjects of childbearing potential (defined as < 2 years after last menstruation and not surgically sterile) and male subjects who are not surgically sterile or with female partners of childbearing potential: absence of effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal gel).
  
  10. Major surgical procedure (including open biopsy, excluding central line IV and portacath) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment.
  
  11. Grade 3 or 4 motor, sensory, or cranial neuropathy symptoms (as defined by CTCAE version 4.0).
  
  12. Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100mm Hg).
  
  13. Clinically significant (i.e. active) cardiovascular disease defined as:
  
  • Stroke within ≤ 6 months prior to day 1;
  
  • Transient Ischemic Attack (TIA) within ≤ 6 months prior to day 1;
  
  • Myocardial infarction within ≤ 6 months prior to day 1;
  
  • Unstable angina;
  - New York Heart Association (NYHA) Grade II or greater Congestive Heart Failure (CHF);
  - Serious cardiac arrhythmia requiring medication;
  - Clinically relevant pathologic findings in ECG. 14. Left Ventricle Ejection Fraction (LVEF) by MUGA or ECHO < 55% for patients receiving 2B3-101 in combination with trastuzumab. For patients receiving single agent 2B3-101 treatment. Left Ventricle Ejection Fraction (LVEF) by MUGA or ECHO < 50%.
    
    15. Known hypersensitivity to any of the study drugs excipients (e.g. doxorubicin, PEG or GSH).
    
    16. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01386580

Locations


United States, North Carolina
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States, 27599
Belgium
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium, B-2650
Jules Bordet Institute
Brussels, Belgium, B-1000
France
Institut Curie
Paris, Paris Cedex 05, France, 75248
Institut Gustave Roussy
Villejuif, Val de Marne, France, 94805
Netherlands
Antoni van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands, 1066 CX
Vrije Universiteit medisch centrum (Vumc)
Amsterdam, Netherlands, 1081 HV
Leids Universitair Medisch Centrum (LUMC)
Leiden, Netherlands, 2333 CA
Maastricht Universitair Medisch Centrum
Maastricht, Netherlands, 6229 HX
Erasmus MC
Rotterdam, Netherlands, 3075 EA

Sponsors and Collaborators

BBB-Therapeutics B.V.

Investigators


Study Director:	J. Veeneman, PhD	BBB Therapeutics

More Information


Responsible Party:	BBB-Therapeutics B.V.
ClinicalTrials.gov Identifier:	NCT01386580 History of Changes
Other Study ID Numbers:	2B3-101-CR-001
First Posted:	July 1, 2011 Key Record Dates
Last Update Posted:	January 22, 2015
Last Verified:	January 2015

Keywords provided by BBB-Therapeutics B.V.:


Brain Neoplasms Neoplasm Metastasis Neoplasms Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site	Brain Diseases Central Nervous System Diseases Nervous System Diseases Neoplastic Processes Pathologic Processes

Additional relevant MeSH terms:


Neoplasm Metastasis Neoplasms, Second Primary Glioma Brain Neoplasms Neoplastic Processes Neoplasms Pathologic Processes Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Central Nervous System Neoplasms	Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases Doxorubicin Liposomal doxorubicin Trastuzumab Antibiotics, Antineoplastic Antineoplastic Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

To Top